期刊文献+

国产匹格列酮片单用及与磺脲类药物合用治疗2型糖尿病的临床疗效 被引量:1

Pioglitazone Hydrochloride Monotherapy or in Combination with Sulfonylurea Therapy Improves Glycemia Control in Patients with Type 2 Diabetes
下载PDF
导出
摘要 目的 观察国产盐酸匹格列酮片单用及与磺脲类药物合用治疗 2型糖尿病患者的临床疗效及安全性。方法  117例 2型糖尿病患者分为单用匹格列酮组 (PIO- mono)和匹格列酮加磺脲类药物组 (PIO- SU) ,进行为期 12周的自身前后对照临床研究。观察治疗前后临床指标及血糖、糖化白红蛋白 (Hb A1 c)、血清胰岛素及 C肽、血脂、游离脂肪酸 (FFA)水平的变化。结果 治疗后 PIO- m ono组 Hb A1 c、空腹及餐后血糖水平较治疗前分别下降了1.6 4 %、 2 .1mmol/ L、 5 .2 mm ol/ L (P<0 .0 1) ,PIO- SU组分别下降了 1.0 6 %、 2 .3mmol/ L、 5 .4 m mol/ L (P<0 .0 1) ,上述指标两组间差别无统计学意义。在血糖水平下降的同时 ,两组空腹及餐后血清胰岛素及 C肽水平均有轻度下降 ,血甘油三酯及游离脂肪酸水平降低 ,HDL - C升高。两组患者药物不良反应发生率相似 ,未观察到肝肾毒性反应。结论 国产匹格列酮片每日 30 mg单用及与磺脲类药物合用治疗 2型糖尿病患者均可有效降低 Hb A1 c和空腹及餐后血糖水平 ,并能减轻胰岛β细胞负荷和改善脂代谢紊乱 。 Objective To evaluate the clinical efficacy and tolerability of pioglitazone monotherapy or in combination with sulfonylurea therapy in the treatment of chinese patients with type 2 diabetes. Methods This 12 week study involved 117 patients with type 2 diabetes whose blood glucose was uncontrolled on a stable regimen of diet or oral sulfonylureas for at least 3 months 〔fasting blood glucose (FBG)7.8 15.0mmol/L; postprandial blood glucose (PBG)>11.1mmol/L)〕. The patients received once daily pioglitazone 30mg plus diet (Group PIO mono) or sulfonylurea (Group PIO SU). The fasting and postprandial plasma glucose, serum insulin, C peptid, lipid profile, free fatty acids (FFAs) levels were measured at baseline and every 4 weeks after treatment. Results All patients showed significant improvement in glycemic control over baseline. There were 1.64%, 2.1 mmol/L, 5.2 mmol/L decrease from baseline HbA1c, FBG and PBG levels in the Group PIO mono and 1.06%, 2.3 mmol/L, 5.4 mmol/L decrease in the Group PIO SU after 12 weeks treatment, respectivley. Both groups experienced slight decreases in C peptide and insulin concentrations during 12 weeks period. Both groups showed mean percent decreases in triglyceride and FFA levels(21.8% and 20.7% for PIO mono, 22.2% and 14.5 for PIO SU) and increases in HDL C( 21.4% for PIO mono and 30.8% for PIO SU), compared with baseline. pioglitazone was well tolerated. Conclusion In patients with type 2 diabetes, pioglitazone monotherapy or in combination with sulfonylurea therapy significantly improves HbA1c , FBG and PBG levels and reserves the β cell function with beneficial effects on serum triglyceride and HDL C levels.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2003年第1期117-120,共4页 Journal of Sichuan University(Medical Sciences)
关键词 临床疗效 2型糖尿病 匹格列酮 磺脲类药物 治疗 Type 2 diabetes Pioglitazone Sulfonylurea
  • 引文网络
  • 相关文献

参考文献4

  • 1[1]Rossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs, 1997; 6(6):1025
  • 2[2]Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medcine, 1999; 16(3): 179
  • 3[3]Kipnes KS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with type 2 diabetes: A randomized, placebo-controlled study. Am J Med, 2001; 111(1):10
  • 4[4]Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care, 2000; 23(11):1605

同被引文献1

引证文献1

;
使用帮助 返回顶部